Inclusion Criteria:

- Prior histologically confirmed anaplastic astrocytoma, anaplastic oligodendroglioma,
anaplastic mixed oligo-astrocytoma, glioblastoma multiforme, or gliosarcoma, for whom
no other effective therapy is available.

- A prior histologic diagnosis of a lower grade of glioma is allowed if there is
current histologic proof of progression to a diagnosis of AA, AO, AOA, GBM or GS

- Unequivocal evidence of recurrence or progression by neuroimaging procedure.

- Surgical resection at least 2 weeks prior to enrollment and must have completely
recovered from the side effects.

- A stable dose of steroids for at least 7 days prior to obtaining the Gd-MRI of the
brain.

- Previously implanted Gliadel® wafer may be eligible.

- Karnofsky Performance Status (KPS) of ≥ 60.

- Laboratory parameters: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin
(Hgb) ≥ 9 g/dl, Platelets ≥ 100 x 109/L, AST and ALT ≤ 3.0 x Upper Limit of Normal
(ULN), Serum bilirubin ≤ 1.5 x ULN, Serum creatinine ≤ 1.5 x ULN and 24 hour
creatinine clearance ≥ 50 ml/min

- Life expectancy of greater than 12 weeks.

- Written informed consent obtained.

Exclusion Criteria:

- Pregnancy or breast feeding, or adults of reproductive potential not employing an
effective method of birth control

- Total urinary protein in 24 hours urine collection > 500 mg

- Any concurrent severe and/or uncontrolled medical conditions which could compromise
participation in the study.

- Impaired cardiac function, other significant prior cardiac disease or arrhythmia of
any

- A history of CHF or arrhythmias.

- Therapeutic doses of warfarin sodium (Coumadin®).

- Prior or concurrent therapy, or not recovered from the toxic effects of such therapy:
investigational drugs, chemotherapy, metronomic daily dosing of chemotherapy agents,
biologic, immunotherapy or cytostatic agents within 4 weeks prior to study entry;
radiation therapy within 2 weeks prior to study entry, any medication known to cause
QT interval prolongation

- Any surgery other than resection of a brain tumor within 2 weeks prior to enrollment.

- A contraindication to MRI imaging.